August 2025, Vol 15, No 8

A coalition of more than 40 health insurers recently announced plans for prior authorization reform. Read More ›

In the United States, between 2006 and 2015, there were approximately 2000 new cases of Merkel cell carcinoma annually, with totals expected to exceed 3200 in 2025. Read More ›

Iman Ahmed, PharmD, BCOP, recently discussed the evidence for what’s actually contributing to health inequities in hematologic malignancies, and how providers can mitigate these disparities. Read More ›

Achieving cancer health equity requires combined structural reforms and individual-level support, along with sustained, collaborative commitment. Read More ›

Officials with the FDA recently approved belzutifan (Welireg; Merck) for people aged ≥12 years with locally advanced unresectable or metastatic pheochromocytoma or paraganglioma (PPGL), making it the first FDA approval of an oral therapy for PPGL. Read More ›

Both single-agent retifanlimab-dlwr (Zynyz; Incyte) and use with carboplatin and paclitaxel have been greenlit for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal. Read More ›

Darolutamide (Nubeqa; Bayer Healthcare Pharmaceuticals) has been approved by the FDA for metastatic castration-sensitive prostate cancer (mCSPC), following an earlier approval to be used in combination with docetaxel for mCSPC. Read More ›

On June 11, 2025, officials with the FDA approved taletrectinib (Ibtrozi; Nuvation Bio), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non–small cell lung cancer. Read More ›

Mitomycin intravesical solution (Zusduri; UroGen Pharma) may now be used to treat adult patients with recurrent intermediate-risk, low-grade, non-muscle invasive bladder cancer after an FDA approval in June. Read More ›

Pembrolizumab (Keytruda; Merck) has received an FDA nod for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 combined positive score ≥1, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy with or without cisplatin after surgery, and then as a single agent. Read More ›

On June 18, 2025, the FDA approved tafasitamab-cxix (Monjuvi; Incyte) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma. Read More ›